- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Amryt Signs Four New Lojuxta Deals in the Middle East
UK-based Amryt, a biopharmaceutical company focused on rare and orphan diseases, has announced the signing of four further distribution agreements for its Homozygous Familial Hypercholesterolaemia (HoFH) treatment, Lojuxta, across the Middle East. The agreements have been signed with Al Hafez Trading Establishment (Kuwait), Ebn Sina Medical (Qatar), Muscat Pharmacy and Stores (Oman), and Goro Healthcare (UAE/Bahrain). Amryt has signed nine distribution agreements for Lojuxta since November 2017. On the latest deals, Joe Wiley, the company's CEO, commented: “The Middle East has a higher HoFH patient population per capita than Europe and we look forward to working closely with our new distribution partners to improve patient outcomes.” An interview with Amryt's Dr. Joe Wiley will feature in the upcoming June issue of Pharmaceutical Executive.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
